Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amy McDonnell

Nurse Practitioner Charlottesville, VA Nurse Practitioner

NPI 1770582702 CMS profile 10541884

1139 E High St, Charlottesville, VA 22902

Open in the dashboard

General payments

$6,949

357 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy McDonnell of Charlottesville, VA is reported in the CMS Open Payments database as having received $6,949 across 357 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,373 112
2024 General $1,691 80
2023 General $1,284 61
2022 General $956 60
2021 General $646 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy McDonnell
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Amy McDonnell were reported at $2,373. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Amy McDonnell Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $646 $135 $40–$426 $132
2022 $956 $152 $48–$470 $149
2023 $1,284 $166 $54–$529 $160
2024 $1,691 $173 $55–$556 $164
2025 $2,373 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,984 97 payments
  2. Janssen Biotech, Inc. $1,124 64 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $721 38 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $539 38 payments
  5. Genzyme Corporation $419 14 payments
  6. QOL Medical, LLC $299 11 payments
  7. Nestle HealthCare Nutrition Inc. $244 12 payments
  8. Celgene Corporation $175 11 payments
  9. Ipsen Biopharmaceuticals, Inc $156 6 payments
  10. Ardelyx, Inc. $151 9 payments
  11. Other $1,139 57 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,949 357 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $852 31 payments
  2. TREMFYA $801 41 payments
  3. STELARA $714 39 payments
  4. XIFAXAN $694 35 payments
  5. LINZESS $601 43 payments
  6. SIMPONI ARIA $522 28 payments
  7. SIMPONI $522 28 payments
  8. CREON $521 38 payments
  9. ENTYVIO $492 35 payments
  10. DUPIXENT $419 14 payments
  11. Other $3,597 182 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

558

Median for Nurse Practitioner: 389

Drug cost

$24,786

Median for Nurse Practitioner: $21,885

Branded share of claims

31.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 20 $10,918
Mesalamine Generic 19 $4,364
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 25 $1,652
Suflave Peg 3350/Sod Sulf,chlr/Pot/Mag Brand 12 $1,424
Budesonide Dr Budesonide Brand 14 $1,375
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 71 $1,367
Omeprazole Generic 154 $1,056
Esomeprazole Magnesium Generic 15 $552
Pantoprazole Sodium Generic 69 $491
Dicyclomine Hcl Generic 39 $472

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$24,787

Medicare's payments for the services billed

Medicare patients

290

Average age 75

Services billed

352

159 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 49%
Depression 28%
Diabetes 24%
Ischemic heart disease 22%
Cancer 20%
Atrial fibrillation 17%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $204
$204 — —
Sucraid
  • QOL Medical, LLC $164
$164 — —
TREMFYA
  • Janssen Biotech, Inc. $140
$140 — —
DUPIXENT
  • GENZYME CORPORATION $125
$125 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $122
$122 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

357 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record